COMMUNIQUÉS West-GlobeNewswire

Aeroflow Health Wins 2025 HME Provider of the Year Award
22/10/2025
Aeroflow Health's innovative approach to patient access, technology integration and partnership development sets a new standard for the home medical equipment industry ASHEVILLE, N.C. and CLEVELAND, Oct. 22, 2025 (GLOBE [...]
Elevara Medicines Raises $70 Million Series A to Advance Phase 2 Rheumatoid Arthritis Trial and Expand Pipeline
22/10/2025
Co-led b y Forbion and Sofinnova Partners, along with founding investor Monograph Capital, and Weatherden Innovative lead program, ELV001, in-licensed by Elevara from Japan’s Teijin Pharma with good tolerability and [...]
Onco3R Therapeutics reports first pre-clinical data from its best-in-class precision oncology portfolio at the 2025 AACR-NCI-EORTC symposium
22/10/2025
Three posters to be presented featuring pre-clinical data of potential best-in-class FGFR3 selective inhibitor, SMARCA2 selective inhibitor, and P53 Y220C reactivator Candidates for FGFR3 and SMARCA2 programs identified [...]
smartbax announces a €4.7 M Pre-Series A round to advance novel antibiotic compound through preclinical stage
22/10/2025
Lead antibacterial compound against a novel target in Gram-negative bacteria validated in infection models Progressing a platform of small-molecule enzymatic activators that induce self-digestion of bacteria as novel [...]
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
22/10/2025
REYKJAVIK, ICELAND (OCTOBER 21, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to its [...]
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
22/10/2025
REYKJAVIK, Iceland, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced [...]
Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
22/10/2025
600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential [...]
Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
22/10/2025
Company previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion’s breakthrough Nociscan solution for chronic low back pain BROOMFIELD, Colo., [...]
Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
22/10/2025
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the [...]
ENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II Development of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
22/10/2025
MELBOURNE, Australia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory [...]
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer
22/10/2025
Basel, October 22, 2025 - Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis’ previously [...]
Ipsen annonce son intention d’acquérir ImCheck Therapeutics et étend son leadership en oncologie avec un portefeuille enrichi de produits en R&D
22/10/2025
Acquisition axée sur le programme clinique phare ICT01 dans le domaine de la leucémie myéloïde aiguë, dont les données issues de l'essai EVICTION de phase I/II en cours ont montré une réponse thérapeutique élevée. ICT01 [...]
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
22/10/2025
Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of [...]
Communiqué de presse : L’efdoralprine alfa de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase II sur l’emphysème par déficit en alpha-1-antitrypsine
22/10/2025
L’efdoralprine alfa de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase II sur l’emphysème par déficit en alpha-1-antitrypsine L’efdoralprine alfa a démontré sa [...]
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
22/10/2025
Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care [...]
Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l'année 2025 et revoit à la hausse ses prévisions pour l'exercice en cours
22/10/2025
Croissance du chiffre d’affaires du Groupe de 12,1 % à taux de change constant 1 au cours des neuf premiers mois de l’année 2025, ou 9,6 % en données publiées, portée par les trois aires thérapeutiques et incluant les [...]
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
22/10/2025
Year-to-date total sales growth of 12.1% at CER 1 , or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline® Further upgrade of full-year 2025 [...]
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
22/10/2025
Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 52 1 Trial showed reduction in annual cumulative steroid dose vs placebo through Week 52; [...]
SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie
22/10/2025
Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie Spineway, spécialiste des implants innovants pour le traitement des pathologies [...]

Pages